BioAtla, Inc. (BCAB) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-02

Key Insights

BioAtla, Inc. is merging its wholly-owned subsidiary BA Merger Sub, Inc. into the parent company, with BioAtla, Inc. as the surviving entity.
The merger will result in a 50-for-1 reverse stock split, where every 50 shares of common stock will be converted into 1 share.
The merger is expected to become effective on April 6, 2026, indicating a significant corporate restructuring event for the company.

Want the newest filings?

This analysis covers the filing from 2026-04-02. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-31

BioAtla, Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025, which provides investors with updated information on the company's financial performance.
The company has updated its corporate presentation, which it plans to use in meetings with investors, investment banks, industry analysts, and potential strategic partners, indicating ongoing efforts to communicate with key stakeholders.
BioAtla, Inc. is an emerging growth company, which means it may have the option to take advantage of certain exemptions from various reporting requirements that are available to public companies.

Filed: 2026-03-23

BioAtla, Inc. has approved retention bonus programs for its key executive officers, including the CFO and CMO, to incentivize them to achieve certain financial and capital raising milestones by August 2026.
The company's shareholders have approved a merger proposal, where BioAtla's wholly-owned subsidiary BA Merger Sub, Inc. will merge with and into BioAtla, Inc., with BioAtla being the surviving entity. This will result in a 50-to-1 share consolidation.
BioAtla did not pay any bonuses to its employees, including executive officers, for 2025, and there will be no salary increases for 2026, indicating financial challenges the company may be facing.

Filed: 2026-03-02

BioAtla, Inc. is undergoing a significant workforce reduction of approximately 70%, indicating a need for cost-containment measures as the company explores strategic options.
The company's Chief Financial Officer, Richard Waldron, is departing, with the Chief Accounting Officer, Chris Vasquez, being appointed as the new CFO.
BioAtla is facing potential delisting from Nasdaq due to non-compliance with the $1.00 bid price requirement and the $2.5 million stockholders' equity requirement.

Filed: 2026-02-09

The Nasdaq Listing and Hearing Review Council has called for a review of the Nasdaq's decision to suspend trading and delist BioAtla's securities, which will stay any suspension or delisting action pending the outcome of the review.
BioAtla believes that Nasdaq's delay in confirming the company's compliance with the market value of listed securities rule, as well as its decision to overturn its policy regarding the use of super-voting stock for a reverse stock split, has caused and will cause irreparable harm to the company.
The company can provide no assurance that the Listing Council's review will result in the continued listing of BioAtla's common stock on Nasdaq.

Filed: 2026-02-06

BioAtla, Inc. (BCAB) received a delisting notice from Nasdaq due to non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements, despite previously meeting the alternative $35 million market value of listed securities requirement.
The company has submitted a request to the Nasdaq Listing and Hearing Review Council to call for an immediate review of the delisting determination and to stay any suspension or delisting action pending the review.
If the common stock is suspended from Nasdaq trading, it would be eligible for quotation on the OTCID market, which may have a material adverse effect on the trading price and volume of the stock.

Filed: 2026-01-30

BioAtla, Inc. (BCAB) filed a Certificate of Elimination to eliminate the Series A Junior Preferred Stock, indicating a simplification of the capital structure.
The company held a special meeting of stockholders to obtain approval for a reverse stock split and the issuance of additional common stock, both of which were ultimately approved.
Despite low retail shareholder participation, the company was able to secure the necessary votes for the reverse stock split by issuing a single share of Series A Junior Preferred Stock to enable the approval.

Filed: 2026-01-12

BioAtla, Inc. issued a single share of Series A Junior Preferred Stock to its Chairman, CEO, and co-founder, granting him super-voting rights on proposals related to a reverse stock split.
The super-voting share allows the holder to cast a number of votes equal to the total outstanding common shares, with the requirement to vote in line with at least two-thirds of the common stock voting power.
The company recently held a special meeting where stockholders approved a potential 20% or more issuance of common stock and the authorization for a reverse stock split in the 1-for-5 to 1-for-20 range.

Filed: 2025-12-31

BioAtla formed a new wholly-owned subsidiary, BA 3021 SPV LLC, to which it will grant an exclusive license to develop and commercialize its CAB-ROR2-ADC clinical asset Oz-V.
BioAtla agreed to sell 35% of the common units of the SPV to Inversagen AI, LLC for $40 million, which it plans to use for Oz-V's Phase 3 clinical study in second-line plus oropharyngeal squamous cell carcinoma.
The transaction is structured in two closings, with the first $5 million closing expected by January 2026 and the second $35 million closing expected by March 2025 upon completion of Inversagen AI's financing.

Filed: 2025-12-30

BioAtla, Inc. received approval from shareholders to issue up to 20% more common stock, which could provide additional financing flexibility.
The company plans to hold a reconvened special meeting on January 12, 2026 to seek shareholder approval for a reverse stock split, which could help boost the share price.
The company was unable to obtain sufficient votes to approve the reverse stock split at the initial special meeting, indicating some shareholder resistance to the proposal.

Other reports for BioAtla, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.